Skip to main content
. 2019 Jun 7;58(18):2657–2662. doi: 10.2169/internalmedicine.2604-18

Figure 4.

Figure 4.

The levels of hepatitis C virus RNA over time in Case 2 treated with direct-acting antiviral agents. The patient was treated for 11 weeks with daclatasvir/asunaprevir, for 12 weeks with ledipasvir/sofosbuvir, and for 12 weeks with glecaprevir/pibrentasvir. The result of the first treatment was viral breakthrough, while relapse followed the subsequent two treatments.